Presentation is loading. Please wait.

Presentation is loading. Please wait.

Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome.

Published byKlara Fredriksson Modified over 5 years ago

Similar presentations

Presentation on theme: "Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome."— Presentation transcript:

1 Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome Analysis  Matthias Guckenberger, MD, Michael Allgäuer, MD, Steffen Appold, MD, Karin Dieckmann, MD, Iris Ernst, MD, Ute Ganswindt, MD, Richard Holy, MD, Ursula Nestle, MD, Meinhard Nevinny-Stickel, MD, Sabine Semrau, MD, Florian Sterzing, MD, Andrea Wittig, MD, Nicolaus Andratschke, MD  Journal of Thoracic Oncology  Volume 8, Issue 8, Pages (August 2013) DOI: /JTO.0b013e318293dc45 Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Patterns of implementation and practice of SBRT in 13 centers in Germany and Austria. SBRT, stereotactic body radiotherapy. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e318293dc45) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Time trend of irradiation dose in stereotactic body radiotherapy. BED, biological effective dose; PTV, planning target volume. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e318293dc45) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 Freedom from local progression for the total patient population. Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e318293dc45) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

5 FIGURE 4 Overall survival for the total patient population.
Journal of Thoracic Oncology 2013 8, DOI: ( /JTO.0b013e318293dc45) Copyright © 2013 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome."

Similar presentations

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review  David.

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review  David.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer  Babatunde A. Yerokun, MD, Chi-Fu.

A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer  Babatunde A. Yerokun, MD, Chi-Fu.
Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,
Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer

Impact of Race on Outcomes of Patients with Non-small Cell Lung Cancer
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 

One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible  Alessandro Brunelli,
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.

Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer? 

Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer? 
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901  Stephen L. Graziano,
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.
Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial 

Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial 
Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J

Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J
Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.

Similar presentations

Ads by Google